Survivor Views

Share

Three Cancer Survivors

Cancer Survivors’ Views Make a Difference

Survivor Views is a groundbreaking program designed to further engage cancer survivors in the important policy issues that are part of ACS CAN’s fight against cancer.  Over 3,000 cancer survivors have agreed to participate in Survivor Views by responding to regular surveys on policy issues that support the prevention, detection and treatment of cancer and promote survivors’ quality of life.

Through Survivor Views, ACS CAN hears directly from cancer survivors about their experiences and their perspectives on critical cancer-related issues.  This information helps shape the development of policy positions and provides important evidence to support the enactment of these policies.

51%

of cancer patients and survivors have gone into debt to cover the cost of their cancer care.

View the survey findings

Latest Updates

February 12, 2025
National

The Senate Budget Committee is scheduled to mark up its budget resolution this week, setting the stage for significant cuts in discretionary spending to offset the cost of the package.

January 28, 2025
National

Eighty-six percent of cancer patients and survivors who receive tax credits to afford Marketplace plans say they would have difficulty getting the care they need without the enhanced premium tax credits, according to the latest Survivor Views survey from ACS CAN.

October 8, 2024
National

Seventy-two percent of cancer patients and survivors support extending the Affordable Care Act enhanced tax credits, according to the latest Survivor Views survey released today by ACS CAN.

May 9, 2024
National

Nearly half (49%) of cancer patients and survivors report being burdened by medical debt alongside some (13%) who report expecting to incur medical debt as part of their treatment plan, according to a new Survivor Views survey by the American Cancer Society Cancer Action Network (ACS CAN).

Survivor Views Resources

Our latest Survivor Views survey finds that across party lines cancer patients and survivors oppose reducing funding for Medicaid (73%), and fewer than one-in-five support adding a work requirement for Medicaid (19%). The survey also finds overwhelming support for protecting coverage for those with preexisting conditions (81%), and explores questions related to allowing non-ACA plans in the marketplace, which a majority (65%) feel would be confusing.

Our latest survey finds that 86% of those receiving enhanced premium tax credits would have difficulty getting care if the credits expire at the end of 2025, and very few (25%) are aware of the enhanced credits expiring.

In our latest survey, cancer patients and survivors overwhelmingly support extending financial assistance for people who purchase health coverage through the Affordable Care Act marketplace by a margin of nearly 12 to 1 (72% support, 6% oppose). The survey also finds 43% would not be able to afford their plan without the enhanced tax credits, 30% would skip or delay medical care to reduce expenses, and 24% would accumulate medical debt to afford their care.

Our latest survey finds that about half of cancer patients and survivors (49%) have incurred medical debt to pay for their cancer care and another 13% expect to incur medical debt as they begin or continue their treatment. Nearly all of those (98%) had health care coverage at the time they accumulated medical debt. This survey also explores the broad health and financial implications of medical debt, how medical debt deepens inequites, and the alarming rate of cancer related medical debt among younger respondents with early diagnoses.

Our latest survey finds that protecting no-cost screenings and preventive care and reducing the burden of medical debt are the most impotant priorities for cancer patients and survivors. This survey also explores the impacts of cancer on food and nutrition insecurity, with impacts felt across income groups and coverage levels.

The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (45%).




Survivor Views is made possible by support from Bristol Myers Squibb, Amgen, Merck, Pfizer, and Sanofi